| scholarly article | Q13442814 |
| P50 | author | Susan Band Horwitz | Q16866414 |
| Lluis A Lopez-Barcons | Q37828984 | ||
| P2093 | author name string | Steven M Keller | |
| Hayley M McDaid | |||
| Han-Guang Yan | |||
| Chia-Ping Huang Yang | |||
| Marie-Emmanuelle Legrier | |||
| Roman Pérez-Soler | |||
| P2860 | cites work | Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control | Q24304179 |
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 11300-11308 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression | |
| P478 | volume | 67 |
| Q37823206 | A comprehensive map of the mTOR signaling network |
| Q52900022 | A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks |
| Q47101798 | Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung cancer cells |
| Q33709656 | Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts |
| Q37255088 | Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications |
| Q35566234 | Clinical development of phosphatidylinositol-3 kinase pathway inhibitors |
| Q28476362 | Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo |
| Q36557486 | Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma |
| Q39887307 | Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer |
| Q37355543 | Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors |
| Q37379562 | Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer |
| Q54367200 | Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. |
| Q37691441 | Emerging MEK inhibitors. |
| Q33604979 | Enhancing mTOR-targeted cancer therapy |
| Q39286775 | Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors |
| Q34579904 | Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma |
| Q37635287 | High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. |
| Q39471795 | Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells. |
| Q37141814 | Inactivation of p53 and Pten promotes invasive bladder cancer |
| Q35944601 | Inhibition of Ras for Cancer Treatment: The Search Continues |
| Q34415484 | Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. |
| Q35640152 | Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence |
| Q34109756 | MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo |
| Q38255064 | Mechanism-based cancer therapy: resistance to therapy, therapy for resistance |
| Q38753126 | Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI. |
| Q50662513 | Modulation of Bax and mTOR for Cancer Therapeutics. |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q39444536 | Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation |
| Q39308503 | PARP cleavage and perturbance in mitochondrial membrane potential by 3-α-propionyloxy-β-boswellic acid results in cancer cell death and tumor regression in murine models. |
| Q33439312 | Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors |
| Q41708717 | Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status |
| Q37716504 | Phosphorylated 4E-BP1 is associated with poor survival in melanoma |
| Q38703546 | Polysome profiling of mAb producing CHO cell lines links translational control of cell proliferation and recombinant mRNA loading onto ribosomes with global and recombinant protein synthesis. |
| Q37733727 | Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. |
| Q35667143 | Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q35679353 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health |
| Q38955246 | Recent advances in targeting mTOR signaling pathway using small molecule inhibitors |
| Q34471836 | Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1–dependent |
| Q37252718 | Role of LKB1 in lung cancer development |
| Q92715575 | SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC |
| Q40377652 | Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation |
| Q38913136 | Significant differences in integration sites of Moloney murine leukemia virus/Moloney murine sarcoma virus retroviral vector carrying recombinant coagulation factor IX in two human cell lines |
| Q24337757 | Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy |
| Q37030376 | Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. |
| Q34754045 | Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. |
| Q37463917 | Targeting mTOR in renal cell carcinoma |
| Q35917446 | The DHX33 RNA Helicase Promotes mRNA Translation Initiation |
| Q39577741 | The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models |
| Q90841086 | The effect of mesenchymal stem cells' secretome on lung cancer progression is contingent on their origin: primary or metastatic niche |
| Q38424397 | Therapies for triple negative breast cancer |
| Q38300326 | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) |
| Q38199737 | Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer |
| Q39952307 | Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line |
| Q38264125 | mTOR pathway: A current, up-to-date mini-review (Review). |
| Q39772743 | mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation |
Search more.